Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab
administered subcutaneously (sc) compared with placebo in the treatment of adult participants
with active psoriatic arthritis. The study includes adalimumab treatment as an active
reference arm.